Atea Pharmaceuticals, Inc. Earnings Per Share (Basic)
Atea Pharmaceuticals, Inc. (AVIR) reported Earnings Per Share (Basic) of -$0.41 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.41.
- Atea Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.57.
- Atea Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.57.
- Atea Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.53.
- Atea Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$1.94.
- Atea Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$2.00.
- Atea Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$1.63.
- Atea Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$1.39, a 195.21% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.41 10-Q · filed 2026-08-12 | -$0.99 10-Q · filed 2026-08-12 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.09 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.57 10-Q · filed 2026-05-12 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.94 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.53 10-Q · filed 2025-11-12 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.37 10-Q · filed 2025-11-12 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.44 10-Q · filed 2026-08-12 | -$0.85 10-Q · filed 2026-08-12 | -$1.24 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | -$0.40 10-Q · filed 2026-05-12 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2024-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.24 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.00 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.37 10-Q · filed 2025-11-12 | -$0.85 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.60 10-Q · filed 2025-11-12 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2024-06-30 | -$0.48 10-Q · filed 2025-08-07 | -$1.23 10-Q · filed 2025-08-07 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.10 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2024-03-31 | -$0.75 10-Q · filed 2025-05-12 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.62 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.63 10-K · filed 2025-03-06 |
| 2023-09-30 | -$0.40 10-Q · filed 2024-11-07 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.16 10-Q · filed 2024-11-07 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-06-30 | -$0.34 10-Q · filed 2024-08-07 | -$0.76 10-Q · filed 2024-08-07 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-03-31 | -$0.43 10-Q · filed 2024-05-14 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-12-31 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.39 10-K · filed 2024-02-28 |
| 2022-09-30 | -$0.10 10-Q · filed 2023-11-08 | -$0.47 derived: net income ÷ weighted average shares · filed 2023-11-08 | -$0.98 10-Q · filed 2023-11-08 | $0.43 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-06-30 | -$0.38 10-Q · filed 2023-08-08 | -$0.88 10-Q · filed 2023-08-08 | $0.52 derived: net income ÷ weighted average shares · filed 2026-04-27 | $0.18 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-03-31 | -$0.51 10-Q · filed 2023-05-08 | $0.90 derived: net income ÷ weighted average shares · filed 2026-04-27 | $0.56 derived: net income ÷ weighted average shares · filed 2026-04-27 | $0.58 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2021-12-31 | $1.41 derived: net income ÷ weighted average shares · filed 2026-04-27 | $1.07 derived: net income ÷ weighted average shares · filed 2026-04-27 | $1.09 derived: net income ÷ weighted average shares · filed 2026-04-27 | $1.46 10-K · filed 2023-02-28 |
| 2021-09-30 | -$0.34 10-Q · filed 2022-11-07 | -$0.32 derived: net income ÷ weighted average shares · filed 2022-11-07 | $0.05 10-Q · filed 2022-11-07 | $0.32 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | $0.02 10-Q · filed 2022-08-08 | $0.39 10-Q · filed 2022-08-08 | $0.72 derived: net income ÷ weighted average shares · filed 2023-02-28 | $0.61 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | $0.37 10-Q · filed 2022-05-10 | $0.74 derived: net income ÷ weighted average shares · filed 2023-02-28 | $0.68 derived: net income ÷ weighted average shares · filed 2023-02-28 | $0.60 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | $0.37 derived: net income ÷ weighted average shares · filed 2023-02-28 | $0.09 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.27 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.51 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.74 10-Q · filed 2021-11-12 | -$2.73 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$3.13 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$0.99 10-Q · filed 2021-08-12 | -$1.39 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$0.40 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$1.39 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |